Anti-VEGFs control CNV, preserve VA in patients with choroidal osteoma

TORONTO — Intravitreal bevacizumab or ranibizumab are useful in treating choroidal neovascularization associated with choroidal osteoma, according to a poster presented at the American Society of Retina Specialists meeting. Exudation was controlled and visual acuity was preserved. The retrospective study included eight patients: seven who presented with blurred vision and one who presented with photopsia. Mean age was 36.5 years; seven of the patients were white women.All patients underwent intravitreal injections of Avastin (bevacizumab, Genentech) or Lucentis (ranibizumab, Genentech).

Full Story →